IMUNON INC. - COMMON

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

25 ноя 2024 08:05:00 Источник Nasdaq GlobeNewswire

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

07 ноя 2024 10:00:00 Источник Nasdaq GlobeNewswire

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

07 ноя 2024 08:05:00 Источник Nasdaq GlobeNewswire

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

31 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

30 окт 2024 09:05:00 Источник Nasdaq GlobeNewswire

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

07 окт 2024 08:05:00 Источник Nasdaq GlobeNewswire

UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

09 сен 2024 16:06:00 Источник Nasdaq GlobeNewswire

IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

09 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire

IMUNON to Host R&D Day on September 18th

28 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

14 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

07 авг 2024 17:04:00 Источник Nasdaq GlobeNewswire

IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

31 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

30 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

29 июл 2024 16:05:00 Источник Nasdaq GlobeNewswire

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

24 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

05 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire

Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

15 май 2024 08:30:00 Источник Nasdaq GlobeNewswire

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

13 май 2024 09:00:00 Источник Nasdaq GlobeNewswire

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

13 май 2024 08:00:01 Источник Nasdaq GlobeNewswire

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

08 май 2024 08:00:00 Источник Nasdaq GlobeNewswire